Merck has paid $35 million Kelun-Biotech to Merck for the exclusive rights to develop, manufacture and commercialize an investigational antibody drug conjugate for treatment of solid tumors.
Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.
